December 08, 2014
A Delaware federal judge on Monday invalidated four Cubist Pharmaceuticals Inc. patents for its blockbuster Cubicin, an intravenous antibiotic used to treat skin and blood infections, potentially clearing the way for Hospira Inc. to sell a generic version in 2016.